TuHURA Biosciences Draws $1.5M on $50M Revolving Credit Facility

What Happened

• TuHURA Biosciences, Inc. filed an 8-K (Sept 4, 2026) disclosing that it drew an additional $1,500,000 on its revolving credit facility on September 2, 2026.
• The revolver was established under a Loan Agreement dated April 21, 2026 with Parkview Holdings One LLC as lender, has a $50 million maximum availability and matures on April 21, 2031. The company said the new funds are expected to be used for general corporate purposes.

Key Details

• Loan Agreement date: April 21, 2026 (lender: Parkview Holdings One LLC).
• Revolving credit maximum availability: $50,000,000; maturity date: April 21, 2031.
• Recent draw: $1,500,000 on September 2, 2026.
• Filing includes standard forward‑looking statement disclosures and notes risks, including potential conflicts of interest involving an affiliate of the company’s largest stockholder.

Why It Matters

• This draw increases TuHURA’s near‑term liquidity by $1.5M and uses debt rather than equity to fund operations, which affects the company’s leverage and remaining borrowing capacity under the $50M revolver.
• Investors should note the lender relationship and the filing’s highlighted risks: the company may face conditions limiting future draws, the facility might not fully cover future cash needs, and potential conflicts of interest are disclosed.
• The 8‑K is a factual update on financing; any impact on long‑term capital needs or operations will depend on future draws, cash burn, and compliance with the Loan Agreement.